TELA Bio market cap is $229.3 m, and annual revenue was $15.45 m in FY 2019

TELA Bio Net income (Q2, 2020)-6.1 M

TELA Bio EBIT (Q2, 2020)-5.2 M

TELA Bio Cash, 30-Jun-202085.5 M

TELA Bio EV174.4 M

USD | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|

## Revenue | 4.2m | 8.3m | 15.4m |

| 95% | ||

## Cost of goods sold | 1.7m | 5.3m | |

## Gross profit | 2.5m | 2.9m | |

| 60% | 36% | |

## Sales and marketing expense | 8.7m | 13.6m | 18.1m |

## R&D expense | 5.8m | 4.3m | 4.2m |

## General and administrative expense | 5.0m | 4.9m | 6.2m |

## Operating expense total | 19.5m | 22.9m | 28.4m |

## EBIT | (16.9m) | (17.8m) | (19.2m) |

| (399%) | (215%) | (124%) |

## Interest expense | 4.6m | 1.8m | |

## Net Income | (21.3m) | (21.1m) | (22.4m) |

USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|---|---|---|---|

## Revenue | 1.6m | 2.1m | 2.2m | 3.3m | 3.3m | 4.0m | 3.7m | 3.5m |

## Cost of goods sold | 1.3m | 1.7m | 845.0k | 1.5m | 1.4m | |||

## Gross profit | 208.0k | 339.0k | 1.4m | 1.8m | 1.9m | |||

| 13% | 16% | 62% | 54% | 58% | |||

## Sales and marketing expense | 2.8m | 3.2m | 3.6m | 4.0m | 3.9m | 4.7m | 5.3m | 4.1m |

## R&D expense | 1.2m | 1.1m | 1.0m | 1.7m | 1.1m | 516.0k | 912.0k | 979.0k |

## General and administrative expense | 944.0k | 1.0m | 1.4m | 1.2m | 2.5m | 2.1m | ||

## Operating expense total | 4.9m | 5.4m | 6.1m | 5.7m | 5.0m | 6.5m | 8.7m | 7.3m |

## EBIT | (4.7m) | (5.1m) | (2.5m) | (5.2m) | (4.3m) | (3.9m) | (6.5m) | (5.2m) |

| (303%) | (243%) | (114%) | (157%) | (130%) | (97%) | (174%) | (147%) |

## Interest expense | 280.0k | 448.0k | 309.0k | 912.0k | 914.0k | 899.0k | ||

## Net Income | (5.0m) | (5.9m) | (2.8m) | (6.0m) | (5.3m) | (4.7m) | (7.2m) | (6.1m) |

USD | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|

## Cash | 11.3m | 17.3m | 45.3m |

## Accounts Receivable | 757.0k | 1.3m | 2.8m |

## Prepaid Expenses | 429.0k | 330.0k | 2.3m |

## Inventories | 1.8m | 4.3m | 4.6m |

## Current Assets | 14.3m | 23.3m | 64.3m |

## PP&E | 1.2m | 758.0k | 677.0k |

## Goodwill | 2.9m | ||

## Total Assets | 15.5m | 27.2m | 67.9m |

## Accounts Payable | 1.5m | 3.4m | 3.2m |

## Short-term debt | 905.0k | ||

## Current Liabilities | 6.1m | 9.6m | 6.7m |

## Long-term debt | 3.6m | 29.7m | |

## Total Debt | 4.5m | 29.7m | |

## Total Liabilities | 12.4m | 40.9m | 37.0m |

## Common Stock | 7.0k | 7.0k | 11.0k |

## Preferred Stock | 111.3m | 124.2m | |

## Additional Paid-in Capital | 198.8m | ||

## Retained Earnings | (108.2m) | (137.9m) | (167.9m) |

## Total Equity | 3.2m | (13.7m) | 31.0m |

## Debt to Equity Ratio | 1.4 x | -2.2 x | |

## Debt to Assets Ratio | 0.3 x | 1.1 x | |

## Financial Leverage | 4.9 x | -2 x | 2.2 x |

USD | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|

## Cash | 15.8m | 10.7m | 41.4m | 85.5m |

## Accounts Receivable | 1.9m | 2.3m | 2.0m | 2.6m |

## Prepaid Expenses | 384.0k | 365.0k | 1.8m | 1.5m |

## Inventories | 4.6m | 4.3m | 4.8m | 4.6m |

## Current Assets | 22.8m | 17.6m | 55.3m | 94.1m |

## PP&E | 712.0k | 716.0k | 693.0k | 678.0k |

## Goodwill | 3.0m | |||

## Total Assets | 26.6m | 23.1m | 58.8m | 97.6m |

## Accounts Payable | 2.1m | 1.7m | 1.4m | 948.0k |

## Current Liabilities | 7.6m | 6.3m | 4.2m | 3.6m |

## Long-term debt | 30.0m | 30.4m | 30.5m | |

## Total Debt | 30.0m | 30.4m | 30.5m | |

## Total Liabilities | 39.3m | 38.1m | 34.6m | 34.1m |

## Common Stock | 7.0k | 11.0k | 14.0k | |

## Preferred Stock | 141.1m | |||

## Additional Paid-in Capital | 199.3m | 244.5m | ||

## Retained Earnings | (153.7m) | (160.4m) | (175.1m) | (181.2m) |

## Total Equity | (12.7m) | (160.4m) | 24.2m | 63.4m |

## Debt to Equity Ratio | -2.4 x | |||

## Debt to Assets Ratio | 1.1 x | |||

## Financial Leverage | -2.1 x | -0.1 x | 2.4 x | 1.5 x |

USD | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|

## Net Income | (21.3m) | (21.1m) | (22.4m) |

## Depreciation and Amortization | 761.0k | 463.0k | 278.0k |

## Accounts Receivable | (578.0k) | (541.0k) | (1.5m) |

## Inventories | (1.8m) | ||

## Accounts Payable | (114.0k) | (62.0k) | (773.0k) |

## Cash From Operating Activities | (16.4m) | (19.9m) | (25.5m) |

## Purchases of PP&E | (114.0k) | (62.0k) | (197.0k) |

## Cash From Investing Activities | (101.0k) | (1.6m) | (12.0m) |

## Short-term Borrowings | (5.7m) | ||

## Long-term Borrowings | (13.0m) | ||

## Cash From Financing Activities | 26.3m | 27.4m | 65.5m |

## Net Change in Cash | 9.9m | 5.9m | 28.0m |

## Interest Paid | 329.0k | 1.1m | 3.1m |

USD | Q2, 2018 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|---|

## Net Income | (10.9m) | (11.2m) | (15.9m) | (7.2m) | (13.3m) |

## Depreciation and Amortization | 309.0k | 135.0k | 206.0k | 56.0k | 95.0k |

## Accounts Receivable | (475.0k) | (599.0k) | (983.0k) | 781.0k | 238.0k |

## Inventories | (1.0m) | (617.0k) | (750.0k) | ||

## Accounts Payable | 324.0k | (1.3m) | (2.5m) | (1.3m) | (2.1m) |

## Cash From Operating Activities | (10.8m) | (13.0m) | (18.3m) | (7.3m) | (13.7m) |

## Purchases of PP&E | (31.0k) | (89.0k) | (164.0k) | (68.0k) | (96.0k) |

## Cash From Investing Activities | (31.0k) | (589.0k) | (2.7m) | 3.9m | 9.2m |

## Short-term Borrowings | (1.5m) | ||||

## Long-term Borrowings | (5.0m) | ||||

## Cash From Financing Activities | 4.8m | 12.2m | 14.4m | (514.0k) | 44.6m |

## Net Change in Cash | (6.1m) | (1.4m) | (6.6m) | (3.9m) | 40.2m |

## Interest Paid | 102.0k | 2.3m | 745.0k | 1.5m |

USD | FY, 2017 |
---|---|

## Revenue/Employee | 95.5k |

## Debt/Equity | 1.4 x |

## Debt/Assets | 0.3 x |

## Financial Leverage | 4.9 x |